Sodium-Glucose Cotransporter 2 Inhibitor Use and Outcomes in Transthyretin Amyloid Cardiomyopathy
JACC Adv
.
2024 Nov 15;3(12):101405.
doi: 10.1016/j.jacadv.2024.101405.
eCollection 2024 Dec.
Authors
Vikash Jaiswal
1
,
Muhammad Hanif
2
,
Yusra Mashkoor
3
,
Akash Jaiswal
4
5
,
Tanisha Prasad
6
,
Kripa Rajak
7
,
Muhammad Shahzeb Khan
8
9
10
,
Robert J Mentz
11
,
Gregg C Fonarow
12
Affiliations
1
Department of Cardiovascular Research, Larkin Community Hospital, South Miami, Florida, United States.
2
Department of Internal Medicine, SUNY Upstate Medical University, Syracuse, New York, USA.
3
Department of Internal Medicine, Dow University of Health Sciences, Karachi, Pakistan.
4
Department of Geriatric Medicine, All India Institute of Medical Science, New Delhi, India.
5
Department of Geriatric Medicine, Fortis Memorial Research Institute, Gurgaon, India.
6
Royal College of Surgeons in Ireland, University of Medicine and Health Science, Dublin, Ireland.
7
Department of Cardiology, University of Missouri, Missouri, United States.
8
Department of Medicine, Baylor School of Medicine, Temple, Texas, United States.
9
Division of Cardiology, Heart Hospital Plano, Plano, Texas, United States.
10
Department of Cardiology, Baylor Scott and White Research Institute, Texas, United States.
11
Division of Cardiology, Duke University School of Medicine, Duke Clinical Research Institute, Durham, North Carolina, USA.
12
Ahmanson-UCLA Cardiomyopathy Center, Ronald Reagan UCLA Medical Center, Los Angeles, California, USA.
PMID:
39817087
PMCID:
PMC11734025
DOI:
10.1016/j.jacadv.2024.101405
No abstract available
Keywords:
SGLT2 inhibitors; amyloidosis; outcomes; transthyretin amyloid cardiomyopathy.